The Illuminator – February 2024

We explored the inner workings of the Illuminator to review the fund’s top 10 holdings, which read like a ‘who’s who’ of Britain’s brightest companies.

GlobalData has completed its five-year growth optimisation plan a year ahead of schedule, with revenue growth of over 50% since 2019. Positive newsflow in the last year includes the 40% stake Inflexion took in GlobalData’s healthcare business in December 2023, at an implied valuation equivalent to c 75% of the group’s then market capitalisation.

GlobalData’s key strength is in its resources of high-quality, proprietary data, accessed via a common scaled platform. The company has been reorganised into three market-facing segments with designated teams providing greater scalability, moving away from the group’s historical centralised model. Furthermore, GlobalData is stepping up investment in AI and natural language processing to improve the customer experience.

GlobalData’s share price has risen 14% over the last year and the stock currently yields c 2.2%.

To read our latest research note on GlobalData, click here.